May 3-4, 2021 | 10:00AM EDT | 2:00PM UTC | 4:00PM CEST*
*Program is in development and subject to change
The live portion of this conference has concluded and all presentations are now available for purchase on demand. Registrants to the live event may access this content anytime for up to 9 months following the event.
Keystone Symposia welcomes the global scientific community and aims to connect researchers within and across disciplines to accelerate the advancement of biomedical and life sciences. This form may be used for scientists from low- and middle-income countries of all career stages to determine eligibility and request free access to scientific content presented during recent eSymposia events. If eligible, you will be sent an access code for the On Demand content of the eSymposia event(s) of interest.
Synthetic Biology tools and principles have matured tremendously over the last decade and have reached extraordinary levels of sophistication, both in eukaryotic and prokaryotic systems. Synthetic biology as a therapeutic modality is starting to enter multiple clinical studies and has the potential to have a significant impact on medicine across a wide range of diseases (e.g., metabolic, immune-mediated, cancer, and neurologic diseases). This Keystone Symposia conference will delve into the field of synthetic biology with a special emphasis on its applications to medicine. While there are conferences that capture synthetic biology in only a few talks mixed in among other various topics, there is a paucity of conferences focused on synthetic biology as drugs to treat disease.
However, due to the rapid pace of fundamental scientific advances along with an expanding number of biotechnology companies and emerging clinical studies with synthetic biology at their core, this conference will be highly relevant for a wide audience of scientists both from academia and industry. In addition, other meetings in this field have a highly technology-driven focus on synthetic biology techniques with relatively little attention given to biological and medical context. Ultimately, this Keystone Symposia conference should inspire researchers from diverse backgrounds to discuss synthetic biology via many new angles.
Regular Registration Rate: $275 USD
Student Registration Rate: $150 USD
Abstract Submission
‣ For Short Talk Consideration: Passed
‣ For ePoster Presentation: Passed
Final ePoster / SciTalk Submission: Passed
Financial Aid Application: Passed
*Abstract submission is required in order to submit an ePoster and/or Scitalk
#VKSSynthBio21
Martin Fussenegger
ETH Zürich, Switzerland
Matthew Chang
National University of Singapore, Singapore
Yvonne Y. Chen
University of California, Los Angeles, USA
Virginia W. Cornish
Columbia University, USA
Luis Ángel Fernández
National Center of Biotechnology - CSIC, Spain
Martin Fussenegger
ETH Zürich, Switzerland
Roger Geiger
Institute for Research in Biomedicine, Switzerland
Jeff Hasty
University of California, San Diego, USA
David Hava
Synlogic, Inc., USA
Howard L. Kaufman
Massachusetts General Hospital, USA
Samira Kiani
University of Pittsburgh School of Medicine, USA
Gary K. Lee
Senti Biosciences, USA
Joshua N. Leonard
Northwestern University, USA
Cammie Lesser
Massachusetts General Hospital, USA
Jose M. Lora
enGene, Inc, USA
Timothy K. Lu
Massachusetts Institute of Technology, USA
Francisco J. Quintana
Harvard Medical School, USA
Owen J. L. Rackham
Duke-NUS, Singapore
Kole T. Roybal
University of California, San Francisco, USA
Zhen Xie
Tsinghua University, China
Funding for this conference was made possible (in part) by 1R13EB029305 - 01 from the National Institute of Biomedical Imaging and Bioengineering. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.
This new virtual meeting format came out of difficult circumstances, but your commitment to scientific progress is what inspired us to launch Keystone eSymposia. In these virtual meetings, we are capturing the same innovative essence of our in-person meetings that you've all created as a scientific community. Here, Debbie Johnson, our CEO, explains how we're going to do that.
